Skip to main content

PerkinElmer Value Stock - Dividend - Research Selection

Perkinelmer

ISIN: US7140461093 , WKN: 850943

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Revvity Board Declares Quarterly Dividend

2024-04-25
WALTHAM, Mass., April 25, 2024--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024.

Revvity's (RVTY) New Launch to Boost Tuberculosis Testing

2024-04-25
Revvity's (RVTY) latest offering is likely to provide a new and improved workflow to lower hands-on time and enable increased lab productivity.

Revvity to Present at BofA Securities 2024 Health Care Conference

2024-04-25
WALTHAM, Mass., April 25, 2024--Revvity, Inc. (NYSE: RVTY) will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 8:40 a.m. PT in Las Vegas, NV.

Revvity’s EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings

2024-04-25
Revvity’s EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic...

Revvity declares $0.07 dividend

2024-04-25
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Revvity Unveils a New Era of Automated Tuberculosis Testing

2024-04-24
WALTHAM, Mass., April 24, 2024--Revvity, Inc. (NYSE: RVTY) today announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 platform is easy to use and designed to provide efficient workflows in the lab. When the accuracy of the T-SPOT.TB test is combined with the efficiency of the Auto-Pure 2400 system, labs, clinicians and ultimately patients, benefit from the resultant powerful solution.

Enphase Energy Reports Weak Results, Joins Lithia Motors And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

2024-04-24
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Investors in Revvity (NYSE:RVTY) have unfortunately lost 25% over the last three years

2024-04-22
As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain...

Revvity's (RVTY) Launch to Boost Pharma-Contract Partner Tie-Up

2024-04-16
Revvity's (RVTY) latest offering is likely to significantly accelerate the pace of drug innovation, with efficient data sharing into one seamless platform.

Revvity Signals Software's New Synergy Solution Redefines Collaboration between Pharma and Contract Partners

2024-04-16
WALTHAM - Revvity, Inc. announced that its software and informatics division, Revvity Signals, will launch Signals SynergyTM , a software solution designed to drive greater collaboration, project...